New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer
September 24, 2020
Mark Pegram, MD, Stanford Women's Cancer CenterMark Pegram, MD, Stanford Women's Cancer Center
, Chau Dang, MD, Memorial Sloan Kettering WestchesterChau Dang, MD, Memorial Sloan Kettering Westchester
, Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer CenterJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center